CN102676663A - Nucleic acid detection kit for detecting BRCA1mRNA - Google Patents
Nucleic acid detection kit for detecting BRCA1mRNA Download PDFInfo
- Publication number
- CN102676663A CN102676663A CN2012101301045A CN201210130104A CN102676663A CN 102676663 A CN102676663 A CN 102676663A CN 2012101301045 A CN2012101301045 A CN 2012101301045A CN 201210130104 A CN201210130104 A CN 201210130104A CN 102676663 A CN102676663 A CN 102676663A
- Authority
- CN
- China
- Prior art keywords
- brca1
- probe
- actin
- nucleic acid
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a nucleic acid detection kit for detecting BRCA1mRNA. The nucleic acid detection kit contains an erythrocyte lysing solution, an RNA extracting solution, a detection system polymerase chain reaction (PCR) reaction solution, a positive control substance and a negative control substance and is characterized in that the detection system PCR reaction solution contains a PCR buffer solution, diethyl-nitrophenyl thiophosphate (dNTP), Mg<2+>, sense/anti-sense primer BRCA1-F/BCA1-R and a probe BRCA1-Probe for detecting and sense/anti-sense primer Actin-F/Actin-R and a probe Actin-Probe, wherein BRCA1-F:CAGCTACCCTTCCATCATAAGTGA; BRCA1-R:GGCCATGTATATGCGAATCTTTTT; BRCA1-Probe:FAM-TTCTGCCCTTGAGGACCTGCGAAAT-TAMRA; Actin-F:TGAGCGAGGCTACAGCTT; Actin-R:TCCTTGATGTCGCGCACGATTT; and Actin-Probe: FAM- ACCACCACGGCCGAGCGG-TAMRA.
Description
Technical field
The invention belongs to life science and biological technical field; Particularly a kind of gene detecting kit adopts the probe for real-time fluorescence quantitative PCR technique, can the BRCA1 expression level in the human breast cancer be detected; Can effectively practice thrift detection time, improve accuracy of detection.
Background technology
Mammary cancer has become the second largest reason of cancer mortality as women's kinds of tumor.Its diagnosis mainly is based upon on the imaging examination basis, lacks laboratory specific diagnosis index, brings difficulty to early diagnosis; Fail to pinpoint a disease in diagnosis easily or mistaken diagnosis, and excision is a mammary cancer first-selection treat-ment, but postoperative influences form; Attractive in appearance not good; The patient is caused bigger puzzlement, the therefore psychological shade of generation of part patient is more arranged, have a strong impact on their quality of life.Think that at present mammary cancer should take the complex therapy of several different methods bonded, the thorough cleaning of primary lesion is the key of breast cancer treatment more.Early diagnosis also seems particularly important in addition, early finds it is the key of striving for its good prognosis.
Mammary cancer 1 gene (breast cancel susceptibility genel; BRCA1) be first found familial breast cancer cancer suppressor gene in the world; Be positioned No. 17 karyomit(e)s long-armed on, by comprising 22 codings exons and 2 non-coding exons.Discover that at present it is one of main mechanism of platinum-based chemotherapy resistance generation that DNA repairs.Clinical application shows that there is significant difference between individuals in the curative effect of platinum medicine, and part patient benefits, and part patient's resistance also toxic side effect occurs.A large amount of clinical studyes are verified: the BRCA1 mrna expression is closely related in the curative effect of platinum medicine and the tumor tissues, and the patient that promptly the BRCA1 gene expression dose is low is responsive to platinum medicine, otherwise the high patient of expression level shows resistance.Yet anti-microtubule based chemotherapy medicine is to act on the cell microtubule, form through influencing spindle body, thereby the inhibition cell mitogen.The efficient low and big problem of spinoff appears treating in this type medicine often, and has significant difference between individuals.Vast amount of clinical shows that the mRNA expression level of BRCA1 gene is closely related in the curative effect of anti-microtubule medicine and the tumor tissues, and the patient that promptly the BRCA1 gene expression dose is high resists microtubule class medicaments insensitive, otherwise the low patient of expression level shows resistance.Thereby the BRCA1 expression level has very important directive function for the medication in later stage.
In practical application; Be used to detect the method that BRCA1 expresses and be mainly immunohistochemical methods, although this method is comparatively directly perceived, process of the test is too loaded down with trivial details; The reagent type that needs is various; And test-results needs veteran expert come interpretation, and there is bigger subjectivity in sentence read result, to a certain degree limit the application of this method.Exactly because there are these problems in the immunohistochemical methods method, just impels us to explore new method and detects the BRCA1 expression level.
The real-time fluorescence quantitative PCR method has higher sensitivity and specificity, and can carry out real-time online to PCR and detect, the initial content of reaction BRCA1 in tissue, and test has been practiced thrift a large amount of detection times, has also avoided the generation of carryover contamination.Common method has SYBR GreenI dye method, two probe hybridization methods and Taqman technology etc.Wherein SYBR GreenI is owing to be non-saturable dye, and specificity must be judged its specificity through observing solubility curve not as two probe hybridization methods and Taqman method; And two probe method hybrid method cost is comparatively expensive.Therefore the present invention adopts the real-time fluorescence PCR technology to combine the Taqman probe method to be applied to the BRCA1 gene test.
Summary of the invention
In view of the deficiency that detects BRCA1 in the prior art, the present invention has designed detection confidential reference items/goal gene with primer, probe sequence, detects the BRCA1 gene with fluorescent quantitative PCR technique.Through adjusting the primer concentration and probe concentration and the ratio of two genes, optimize reaction system and the reaction conditions of PCR, developed a kind of kit for detecting nucleic acid that is used to detect BRCA1mRNA.
Be used to detect the kit for detecting nucleic acid of BRCA1mRNA, comprise erythrocyte cracked liquid, RNA extracting solution, detection architecture PCR reaction solution, positive reference substance and negative control article; It is characterized in that:
Detection architecture PCR reaction solution comprises PCR damping fluid, d NTP, Mg
2+, detect use downstream primer BRCA1-F/BRCA1-R and probe BRCA1-Probe, with reference to using downstream primer Actin-F/Actin-R probe Actin-Probe; Wherein,
BRCA1-F:CAGCTACCCTTCCATCATAAGTGA
BRCA1-R:GGCCATGTATATGCGAATCTTTTT
BRCA1-Probe:FAM-TTCTGCCCTTGAGGACCTGCGAAAT-TAMRA
Actin-F:TGAGCGAGGCTACAGCTT
Actin-R:TCCTTGATGTCGCGCACGATTT
Actin-Probe:FAM-ACCACCACGGCCGAGCGG-TAMRA。
Further, detecting the ratio of using downstream primer and probe is preferably: the mol ratio of BRCA1-F: BRCA1-R: BRCA1-Probe is 2: 2: 1.
Ratio with reference to using downstream primer and probe is preferably: the mol ratio of Actin-F: Actin-R: Actin-Probe is 2: 2: 1.
Said positive reference substance is for containing the genomic solution of BRCA1; Said negative control article are the genomic solution of no BRCA1.
The RNA extracting solution can use commerical prod QIAGEN RNeasy FFPE Kit paraffin RNA extraction agent box to substitute.
Use test kit of the present invention, the real-time fluorescence PCR technology is combined to adopt the Tapman probe, can detect BRCA1mRNA, accuracy of detection is high, and simple to operate, can reduce the detection cost, practices thrift detection time.Utilize two calibration curve methods; Detected result is compared with normal people's expression level (0.75); Whether can weigh the interior BRCA1 gene expression dose of testee's body normal; This method is a kind of novel method that is used for evaluate patient BRCA1 expression level, also helps patient's anaphase scheme determination.Substituted original simple individual detection owing to introduced " normal people "; Not only can detect BRCA1 gene expression amount in testee's body; Can also compare with normal level simultaneously; Instruct the later stage medication, can be used for auxiliary early diagnosis, early prevention and the high risk population's of mammary cancer screening clinically.
Description of drawings
Fig. 1 is the positive test symbol synoptic diagram;
Fig. 2 is the negative result synoptic diagram.
Embodiment
Embodiment 1
The kit for detecting nucleic acid that is used to detect BRCA1mRNA of the present invention comprises:
Erythrocyte cracked liquid;
RNA extracting solution: QIAGEN RNeasy FFPE Kit.
Detection architecture PCR reaction solution: THUNDERBIRD Probe qPCR Mix (2 *) (comprises PCR damping fluid, d NTP, Mg
2+), each 0.8uM of BRCA1 primer, BRCA1-probe (probe) 0.4uM; Each 0.8uM of Actin primer, Actin-probe (probe) 0.4uM; Wherein,
BRCA1-F:CAGCTACCCTTCCATCATAAGTGA,
BRCA1-R:GGCCATGTATATGCGAATCTTTTT,
BRCA1-Probe:FAM-TTCTGCCCTTGAGGACCTGCGAAAT-TAMRA,
Actin-F:TGAGCGAGGCTACAGCTT,
Actin-R:TCCTTGATGTCGCGCACGATTT,
Actin-Probe:FAM-ACCACCACGGCCGAGCGG-TAMRA;
Positive reference substance: contain BRCA1 genome solution;
Negative control article: do not contain BRCA1 genome solution.
Embodiment 2
The method of use of test kit of the present invention:
(1) organizes RNA in the extracting paraffin section: cut tissue or paraffin sheet sample and in the 1.5ml centrifuge tube, (scrape); Add 1ml transparency of organization liquid, the centrifugal 1min of 13000rpm behind the vibration mixing; The centrifugal 1min of 13000rpm behind the removal supernatant adding 500ml transparency of organization liquid vibration mixing; Remove supernatant, the centrifugal 1min of 13000rpm behind the adding 1ml absolute ethyl alcohol vibration mixing; Spend metal bath 10min (uncapping) as for 37 behind the removal supernatant, until liquid dried; With reference to QIAGEN RNeasy FFPE Kit paraffin RNA extraction agent box specification sheets, extract sample rna.
(2) with reference to the Rever Tra Ace qPCR RT Kit test kit specification sheets of TOYOBO company, RNA is reversed to cDNA.
(3) reagent configuration: by detecting each X ul of people's umber configuration detection system PCR reaction solution, everyone part 23ul packing:
X=23ul reaction solution * (8 parts of confidential reference items (typical curve)+8 part goal gene (typical curve)+n part sample+1 part of positive control+1 part negative control+1 part of blank).
(4) application of sample: add 2ulcDNA in the detection architecture PCR reaction solution; Positive control and negative control directly add 2ul positive reference substance and negative control article; Blank adds 2ul saline water or does not add any material.
(5) detect: detect and on the real-time fluorescence PCR appearance, carry out, available instrument comprises ABI7300,7500 (U.S. Applied Biosystems companies) etc.Reaction conditions: 95 ℃ of preparatory sex change 1min; 95 ℃ of 15s, 40 circulations of 58 ℃ of 35sec, fluorescent signal is gathered when 58 ℃ of 35sec.
(6) result judges: threshold line is adjusted to background signal and negative the amplification more than the line, and system calculates copy number automatically according to typical curve and CT value.Calculate according to following formula:
1) control group is the normal people, and the ratio of its goal gene/house-keeping gene is stabilized in about 0.75 through the test of great amount of samples.
2) F value>1.5, it is higher to be judged as expression amount; F value<0.5, it is on the low side to be judged as expression amount; 0.5<F<1.5 are judged as normal.
3) positive judgement criteria:, Ct<36, positive; 35≤Ct≤38 are the doubtful positive, need checking once more; Ct>38, negative.
Embodiment 3
Adopt nucleic acid detection method of the present invention to detect clinical samples
Fetch and deliver patient with breast cancer's's (adopting two-tube fluorescent quantitative PCR technique) of inspection paraffin section sample 20 examples, press embodiment 2 said methods and extract geneome RNA, reagent preparation and detection.
Every part of sample adds 2ul in the detection architecture PCR reaction solution.Do the positive simultaneously, feminine gender, blank, each portion of the typical curve of internal control gene/goal gene.The fluorescent PCR appearance in one 96 hole can detect 20 duplicate samples simultaneously, and each sample repeats a positive control, a negative control and a blank 2 times.Be merely 100 minutes detection time.
Experimental result is compared with reporting the result of PCR group, confirms the accuracy rate of sample detection.Part positive findings such as following table:
Sample | The confidential reference items expression amount | The BRCA1 expression amount | Ratio | Ratio with the normal people | Expression level |
3108 | 89.02 | 220.05 | 2.47 | 3.30 | High |
3101 | 3.09 | 9.68 | 3.13 | 4.18 | High |
11713 | 20.14 | 13.19 | 0.65 | 0.87 | Normally |
3110 | 23.25 | 39.94 | 1.72 | 2.29 | High |
3301 | 5.61 | <1 | 0.00 | 0.00 | Negative |
3325 | 37.15 | 33.8 | 0.91 | 1.21 | Normally |
3531 | 2.56 | 12.86 | 5.02 | 6.70 | High |
3106 | 5.73 | 12.74 | 2.22 | 2.96 | High |
3518 | 19.73 | 17.51 | 0.89 | 1.18 | Normally |
3321 | 78.06 | 167.35 | 2.14 | 2.86 | High |
3312 | 53.27 | 54.02 | 1.01 | 1.35 | Normally |
3320 | 12.43 | 6.9 | 0.56 | 0.74 | Normally |
21258 | 36.15 | 55.9 | 1.55 | 2.06 | High |
3304 | 67.17 | 144.67 | 2.15 | 2.87 | High |
3502 | 20.32 | 197.07 | 9.70 | 12.93 | High |
3302 | 69.38 | 377.12 | 5.44 | 7.25 | High |
522695 | 52.38 | 834.07 | 15.92 | 21.23 | High |
522664 | 3.15E-01 | Do not detect | 0.00 | 0.00 | Negative |
3322 | 7.73 | 8.68 | 1.12 | 1.50 | Normally |
3329 | 39.31 | 13.23 | 0.34 | 0.45 | Low |
Table 1 is this result of experiment
Can find out have 11 examples to be high expression level in the 20 routine samples from last table, 6 examples are normal expression, and 1 example is expressed for low, and 2 examples are negative.Exactly because introduced normal people's numerical value as reference, finally can estimate, thereby instruct anaphase and medication to testee's BRCA1 expression level.Not only accuracy is high as a result for this method, and for clinical certain directive significance is arranged.
Embodiment 4 clinical samples detect
Get clinical sample to be checked 1 and sample 2, press embodiment 2 said methods and extract genome, reagent preparation and detection.
Every duplicate samples adds 2ul in the detection architecture PCR reaction solution.Do the positive simultaneously, feminine gender, each portion of blank.Detect with the fluorescent PCR appearance, the time is 100 minutes.
The detected result figure of sample 1 is as shown in Figure 1, and the amplified signal of internal control gene actin shows that seized sample genome extracts successfully, and detected result is effective, before CT value<36 of sample 1 amplified signal is arranged, so sample 1 is positive.
The detected result figure of sample 2 is as shown in Figure 2, and the amplified signal of internal control gene actin shows that seized sample genome extracts successfully, and detected result is effective, does not have amplified signal after CT value>38 of sample 2, so sample 2 is negative.
SEQUENCE?LISTING
< 110>Hangzhou Ai Dikang medical test center ltd
< 120>be used to detect the kit for detecting nucleic acid of BRCA1mRNA
<130>
<160> 6
<170> PatentIn?version?3.3
<210> 1
<211> 24
<212> DNA
< 213>artificial sequence
<400> 1
cagctaccct?tccatcataa?gtga 24
<210> 2
<211> 24
<212> DNA
< 213>artificial sequence
<400> 2
ggccatgtat?atgcgaatct?tttt 24
<210> 3
<211> 25
<212> DNA
< 213>artificial sequence
<400> 3
ttctgccctt?gaggacctgc?gaaat 25
<210> 4
<211> 18
<212> DNA
< 213>artificial sequence
<400> 4
tgagcgaggc?tacagctt 18
<210> 5
<211> 22
<212> DNA
< 213>artificial sequence
<400> 5
tccttgatgt?cgcgcacgat?tt 22
<210> 6
<211> 18
<212> DNA
< 213>artificial sequence
<400> 6
accaccacgg?ccgagcgg 18
Claims (4)
1. be used to detect the kit for detecting nucleic acid of BRCA1mRNA, comprise erythrocyte cracked liquid, RNA extracting solution, detection architecture PCR reaction solution, positive reference substance and negative control article; It is characterized in that:
Detection architecture PCR reaction solution comprises PCR damping fluid, d NTP, Mg
2+, detect use downstream primer BRCA1-F/BRCA1-R and probe BRCA1-Probe, with reference to using downstream primer Actin-F/ Actin-R probe Actin-Probe; Wherein,
BRCA1-F:CAGCTACCCTTCCATCATAAGTGA
BRCA1-R:GGCCATGTATATGCGAATCTTTTT
BRCA1-Probe:FAM-TTCTGCCCTTGAGGACCTGCGAAAT-TAMRA
Actin-F:TGAGCGAGGCTACAGCTT
Actin-R:TCCTTGATGTCGCGCACGATTT
Actin-Probe:FAM-ACCACCACGGCCGAGCGG-TAMRA。
2. kit for detecting nucleic acid as claimed in claim 1, the mol ratio that it is characterized in that BRCA1-F ︰ BRCA1-R ︰ BRCA1-Probe are 2 ︰, 2 ︰ 1.
3. kit for detecting nucleic acid as claimed in claim 1, the mol ratio that it is characterized in that Actin-F ︰ Actin-R ︰ Actin-Probe are 2 ︰, 2 ︰ 1.
4. kit for detecting nucleic acid as claimed in claim 1 is characterized in that said positive reference substance is for containing the genomic solution of BRCA1; Said negative control article are the genomic solution of no BRCA1.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201210130104 CN102676663B (en) | 2012-04-27 | 2012-04-27 | Nucleic acid detection kit for detecting BRCA1mRNA |
CN201310365818.9A CN103451282B (en) | 2012-04-27 | 2012-04-27 | For detecting the kit for detecting nucleic acid of BRCA1mRNA |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201210130104 CN102676663B (en) | 2012-04-27 | 2012-04-27 | Nucleic acid detection kit for detecting BRCA1mRNA |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310365818.9A Division CN103451282B (en) | 2012-04-27 | 2012-04-27 | For detecting the kit for detecting nucleic acid of BRCA1mRNA |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102676663A true CN102676663A (en) | 2012-09-19 |
CN102676663B CN102676663B (en) | 2013-09-25 |
Family
ID=46809212
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310365818.9A Active CN103451282B (en) | 2012-04-27 | 2012-04-27 | For detecting the kit for detecting nucleic acid of BRCA1mRNA |
CN 201210130104 Active CN102676663B (en) | 2012-04-27 | 2012-04-27 | Nucleic acid detection kit for detecting BRCA1mRNA |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310365818.9A Active CN103451282B (en) | 2012-04-27 | 2012-04-27 | For detecting the kit for detecting nucleic acid of BRCA1mRNA |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN103451282B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103589786A (en) * | 2013-09-27 | 2014-02-19 | 吉林艾迪康医学检验所有限公司 | Method, kit, primer and probe for detecting relative expression quantity of RRM1 (ribonucleotide reductase M1) mRNA (messenger ribonucleic acid) |
CN104862397A (en) * | 2015-05-15 | 2015-08-26 | 杭州艾迪康医学检验中心有限公司 | Primers and method for detecting relative expression of mRNA (messenger ribonucleic acid) of TOPO IIa (topoisomerase IIa) |
CN105420393A (en) * | 2015-12-30 | 2016-03-23 | 武汉海吉力生物科技有限公司 | Primers, probe, and kit for detecting BRCA1 gene expression |
CN109234362A (en) * | 2018-10-15 | 2019-01-18 | 北京艾迪康医学检验实验室有限公司 | Detect oligonucleotides, method and the kit of CLTC-TFE3 fusion in sample |
CN112266959A (en) * | 2020-10-19 | 2021-01-26 | 杭州艾迪康医学检验中心有限公司 | Reagent and method for quantitatively detecting mTOR mRNA relative expression in sample |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103451282B (en) * | 2012-04-27 | 2015-10-14 | 杭州艾迪康医学检验中心有限公司 | For detecting the kit for detecting nucleic acid of BRCA1mRNA |
CN103940998B (en) * | 2014-05-04 | 2016-04-20 | 山东大学 | The application of the early diagnosis marker that serum microRNA shifts as hepatocellular carcinoma |
TWI702291B (en) * | 2018-12-28 | 2020-08-21 | 薩摩亞商康多富國際有限公司 | Method for determining a set of personalized cancer healthy foods and non-transitory computer readable storage medium |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102312002A (en) * | 2011-09-20 | 2012-01-11 | 李艳 | Kit for rapid detection of mRNA expression level of BRCA1 gene |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103451282B (en) * | 2012-04-27 | 2015-10-14 | 杭州艾迪康医学检验中心有限公司 | For detecting the kit for detecting nucleic acid of BRCA1mRNA |
-
2012
- 2012-04-27 CN CN201310365818.9A patent/CN103451282B/en active Active
- 2012-04-27 CN CN 201210130104 patent/CN102676663B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102312002A (en) * | 2011-09-20 | 2012-01-11 | 李艳 | Kit for rapid detection of mRNA expression level of BRCA1 gene |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103589786A (en) * | 2013-09-27 | 2014-02-19 | 吉林艾迪康医学检验所有限公司 | Method, kit, primer and probe for detecting relative expression quantity of RRM1 (ribonucleotide reductase M1) mRNA (messenger ribonucleic acid) |
CN103589786B (en) * | 2013-09-27 | 2016-08-17 | 吉林艾迪康医学检验所有限公司 | Method, test kit and the primer of detection RRM1 mRNA relative expression quantity and probe |
CN104862397A (en) * | 2015-05-15 | 2015-08-26 | 杭州艾迪康医学检验中心有限公司 | Primers and method for detecting relative expression of mRNA (messenger ribonucleic acid) of TOPO IIa (topoisomerase IIa) |
CN105420393A (en) * | 2015-12-30 | 2016-03-23 | 武汉海吉力生物科技有限公司 | Primers, probe, and kit for detecting BRCA1 gene expression |
CN109234362A (en) * | 2018-10-15 | 2019-01-18 | 北京艾迪康医学检验实验室有限公司 | Detect oligonucleotides, method and the kit of CLTC-TFE3 fusion in sample |
CN112266959A (en) * | 2020-10-19 | 2021-01-26 | 杭州艾迪康医学检验中心有限公司 | Reagent and method for quantitatively detecting mTOR mRNA relative expression in sample |
Also Published As
Publication number | Publication date |
---|---|
CN103451282B (en) | 2015-10-14 |
CN102676663B (en) | 2013-09-25 |
CN103451282A (en) | 2013-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102676663B (en) | Nucleic acid detection kit for detecting BRCA1mRNA | |
Kim et al. | Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung | |
Sherwood et al. | Characteristics, properties, and potential applications of circulating cell-free dna in clinical diagnostics: a focus on transplantation | |
US20080233573A1 (en) | Gene expression profiling for identification, monitoring and treatment of transplant rejection | |
JP6606554B2 (en) | Use of the methylated site of the Y chromosome as a diagnostic marker for prostate cancer | |
JP2011501964A (en) | Prognostic prediction process of squamous cell lung cancer | |
US11603566B2 (en) | Methods for diagnosing and treating esophageal cancer | |
US20200332363A1 (en) | Methods for predicting risk of recurrence and/or metastasis in soft tissue sarcoma | |
Li et al. | Quick recovery and characterization of cell-free DNA in seminal plasma of normozoospermia and azoospermia: implications for non-invasive genetic utilities | |
CN102719540A (en) | Detection kit for detecting relative expression level of PML-RAR (alpha) fusion gene by use of fluorescent quantitative PCR (polymerase chain reaction) technology | |
CN109055555A (en) | A kind of lung cancer transfer diagnosis marker and its kit and application in early days | |
CN102649977B (en) | Kit for detecting relative expression index of leukemia BCR/ABL (m-bcr) fusion gene | |
Deutsch et al. | Application of salivary noncoding microRNAs for the diagnosis of oral cancers | |
CN102758011A (en) | Nucleic acid detection kit for detecting ERCC1mRAN | |
CN109136373A (en) | It is a kind of for early diagnosing the lncRNA detection kit and its application of lung cancer metastasis | |
US10590463B2 (en) | Diagnostic methods and kits for monitoring response to chemotherapy in ovarian cancer | |
CN103589786B (en) | Method, test kit and the primer of detection RRM1 mRNA relative expression quantity and probe | |
CN102758006B (en) | Kit for detecting relative expression of leukemia BCR/ABL (b3a2, b2a2) fusion gene | |
Meira-Strejevitch et al. | Reference genes for studies in infectious parasitic diseases in five types of human tissues | |
JP6755518B2 (en) | How to determine the prognosis of blood disorders | |
CN110358829A (en) | Detect application and the kit of the reagent of recombined human peptidyl prolyl cis-trans isomerase-H expression | |
CN102776282B (en) | Kit for detecting relevant expression quantity of AML-EVI1 (acute myelocytic leukemia-ecotropic virus integration site 1) fusion gene | |
SH et al. | Relationship between microRNA-206 plasma levels with the severity of coronary artery conflicts in patients with coronary artery disease. | |
CN104862397A (en) | Primers and method for detecting relative expression of mRNA (messenger ribonucleic acid) of TOPO IIa (topoisomerase IIa) | |
CN109321640A (en) | Detect oligonucleotides, method and the kit of PSF-TFE3 fusion in sample |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |